Gold Fund News | The concept of contract research organizations (CRO) is generally rising. As of press time, Pharmaron (03759) has risen 6.66%, Viva Biotech (01873) has risen 5.05%, Tigermed (03347) has risen 2.84%, and Wuxi Bio (02269) has risen 2.77%.
On the news front, Orient Securities said that according to the latest data on the key indicators of the CRO industry's business outlook: global funding has basically stabilized, while domestic investment and financing are still tight; and the enthusiasm for research and development remains high, with IND and new clinical trials still at high levels. The bank believes that the CXO sector is expected to experience marginal improvement after experiencing double kills in performance and valuation. Fangda Securities believes that domestic CXO companies are stepping rapidly into emerging fields, expanding new categories, accelerating related layouts, and hoping to undertake global related production capacity needs, and will gain new growth on the road to growth in the next five years.
In addition, leading company Pharmaron released a profit forecast for the half-year ended June 30, 2024. The net profit attributable to the company's shareholders is expected to be between 1.055 billion yuan and 1.143 billion yuan, a year-on-year increase of approximately 34%-45%.